International Journal of Hematology

, Volume 108, Issue 6, pp 571–579 | Cite as

The number of CD34+CD133+ hematopoietic stem cells residing in umbilical cord blood (UCB) units is not correlated with the numbers of total nucleated cells and CD34+ cells: a possible new indicator for quality evaluation of UCB units

  • Yoshikazu Matsuoka
  • Fumiaki Nakamura
  • Kazuo Hatanaka
  • Tatsuya Fujioka
  • Satoshi Otani
  • Takafumi Kimura
  • Yoshihiro Fujimura
  • Hiroaki Asano
  • Yoshiaki SonodaEmail author
Original Article


Umbilical cord blood transplantation (UCBT) is often associated with delayed neutrophil and platelet recovery. Engraftment failure is another major obstacle. Several factors influence these serious complications, including the numbers of total nucleated cells (TNCs) and CD34+ cells which have been used as reliable factors for selecting UCB units for transplantation. However, whether both factors are reliable indices of the hematopoietic stem cell (HSC) activity of UCB units remains unknown. To evaluate the quality of UCB units, we quantified the actual number of transplantable CD34+CD133+ HSCs (tHSCs) residing in UCB units. The number of tHSCs was not correlated with the numbers of TNCs or CD34+ cells. These results strongly suggest that neither factor reflects the numbers of tHSCs residing in UCB units. To validate the significance of the number of tHSCs, further analysis is required to determine whether the number of tHSCs residing in UCB units is useful as a new indicator for the quality assessment of UCB units.


CD34+CD133+ HSCs UCBT Quality assurance UCB units 



This work was supported by Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan. The authors are grateful to the Japanese Red Cross Kinki Cord Blood Bank for providing the CB samples used in this study. Drs. S. Nomura, S. Fujita, H. Ogawa, M. Inoue and H. Nakamae are acknowledged for their valuable contribution to this study.

Author Contributions

YM, designed and performed a majority of the experiments, analyzed and interpreted the data; FN, KH, TF, contributed to the data analysis and interpretation; SO, TK, YF, designed and performed some of the experiments, analyzed and interpreted the data; HA, provided advice on the statistical analyses; YS, conceived of and designed the study, analyzed and interpreted the data, provided financial and administrative support, and wrote the paper.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12185_2018_2502_MOESM1_ESM.docx (71 kb)
Supplementary material 1 (DOCX 71 KB)


  1. 1.
    Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–8.CrossRefGoogle Scholar
  2. 2.
    Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol. 2011;154:441–7.CrossRefGoogle Scholar
  3. 3.
    Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491–8.CrossRefGoogle Scholar
  4. 4.
    Metheny L, Caimi P, de Lima M. Cord blood transplantation: can we make it better? Front Oncol. 2013;3:238.CrossRefGoogle Scholar
  5. 5.
    Kerke N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124:334–43.CrossRefGoogle Scholar
  6. 6.
    Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106.CrossRefGoogle Scholar
  7. 7.
    Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transpl. 2013;19:552–615.CrossRefGoogle Scholar
  8. 8.
    Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–8.PubMedGoogle Scholar
  9. 9.
    Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815–22.CrossRefGoogle Scholar
  10. 10.
    Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placenta-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77.CrossRefGoogle Scholar
  11. 11.
    Matsuno N, Wake A, Uchida N, Ishiwata K, Araoka H, Takagi S, et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood. 2009;114:1689–95.CrossRefGoogle Scholar
  12. 12.
    Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115:1843–9.CrossRefGoogle Scholar
  13. 13.
    Krause DS, Fackler MJ, Civin CI, May WS. CD34: Structure, biology, and clinical utility. Blood. 1996;87:1–13.PubMedGoogle Scholar
  14. 14.
    Radtke S, Görgens A, Kordelas L, Schmidt M, Kimmig KR, Köninger A, et al. CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants. Br J Haematol. 2015;169:868–78.CrossRefGoogle Scholar
  15. 15.
    Theilgaard-Mönch K, Raaschou-Jensen K, Palm H, Schjødt K, Heilmann C, Vindeløv L, et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transpl. 2001;28:1073–82.CrossRefGoogle Scholar
  16. 16.
    Takahashi M, Matsuoka Y, Sumide K, Nakatsuka R, Fujioka T, Kohno H, et al. CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34–negative hematopoietic stem cells. Leukemia. 2014;28:1308–15.CrossRefGoogle Scholar
  17. 17.
    Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guideline for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–26.CrossRefGoogle Scholar
  18. 18.
    Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175–82.CrossRefGoogle Scholar
  19. 19.
    Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y, et al. SCID-repopulating cell activity of human cord blood-derived CD34 cells assured by intra-bone marrow injection. Blood. 2003;101:2924–31.CrossRefGoogle Scholar
  20. 20.
    Matsuoka Y, Sumide K, Kawamura H, Nakatsuka R, Fujioka T, Sonoda Y. GPI-80 expression highly purifies human cord blood-derived primitive CD34-negative hematopoietic stem cells. Blood. 2016;128:2258–60.CrossRefGoogle Scholar
  21. 21.
    Kimura T, Asada R, Wang J, Kimura T, Morioka M, Matsui K, et al. Identification of long-term repopulating potential of human cord blood-derived CD34flt3 severe combined immunodeficiency-repopulating cells by intra-bone marrow injection. Stem Cells. 2007;25:1348–55.CrossRefGoogle Scholar
  22. 22.
    Kimura T, Matsuoka Y, Murakami M, Kimura T, Takahashi M, Nakamoto T, et al. In vivo dynamics of human cord blood-derived CD34 SCID-repopulating cells using intra-bone marrow injection. Leukemia. 2010;24:162–8.CrossRefGoogle Scholar
  23. 23.
    Hu Y, Smyth GK. ELDA. Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–8.CrossRefGoogle Scholar
  24. 24.
    Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.CrossRefGoogle Scholar
  25. 25.
    Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.CrossRefGoogle Scholar
  26. 26.
    Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haematopoietic stem-cell transplantation in adults with acute leukemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.CrossRefGoogle Scholar
  27. 27.
    Martin PS, Li S, Nikiforow S, Alyea EP 3rd, Antin JH, Armand P, et al. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:499–505.CrossRefGoogle Scholar
  28. 28.
    Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000;96:2717–22.PubMedGoogle Scholar
  29. 29.
    Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T, et al. Total colony-forming units are strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transpl. 2011;17:1362–74.CrossRefGoogle Scholar
  30. 30.
    Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–20.CrossRefGoogle Scholar
  31. 31.
    Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Yoshikazu Matsuoka
    • 1
  • Fumiaki Nakamura
    • 2
  • Kazuo Hatanaka
    • 3
  • Tatsuya Fujioka
    • 1
  • Satoshi Otani
    • 4
  • Takafumi Kimura
    • 4
  • Yoshihiro Fujimura
    • 4
  • Hiroaki Asano
    • 5
  • Yoshiaki Sonoda
    • 1
    Email author
  1. 1.Department of Stem Cell Biology and Regenerative Medicine, Graduate School of Medical ScienceKansai Medical UniversityHirakataJapan
  2. 2.Clinical Development and Operations, Product Development DepartmentBayer Yakuhin, LtdOsakaJapan
  3. 3.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  4. 4.Japanese Red Cross Kinki Block Blood CenterOsakaJapan
  5. 5.Graduate School of Nursing for Health Care ScienceKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations